Member Info for Brand

https://clinicalresearch.uhs.nhs.uk/news/professor-tom-wilkinson-named-a-senior-leader-in-uk-respiratory-research

Professor Tom Wilkinson, Respiratory and Allergy theme lead at our NIHR Southampton Biomedical Research Centre, has been recognised as one of the most prominent health researchers in the UK.

Prof Wilkinson has been appointed an NIHR Senior Investigator. The prestigious honour from the National Institute for Health and Care Research (NIHR) underlines his status as an outstanding research leader.

He is one of only around 200 members of the NIHR College of Senior Investigators. The College includes six other senior researchers from Southampton.

https://www.fiercebiotech.com/biotech/verus-eua-ambitions-crash-after-fda-declines-authorize-its-covid-treatment

I think that's a really important takeaway. It's not narcissistic, it's not personality disorders - it's organised, tactical and targeted.

Lol this is golden. Nice find Tommy. Should probably be pinned to the top of this board

I reckon professional is so flush after all of his expert level trading he should buy the report and share it w the rest of us.

https://link.springer.com/article/10.1007/s10875-023-01452-4

How could I forget Axe - one for you here mate

And one more for Andy, cause he's my favourite:)

This one - has to be for professional

This one for Mr Costs

Bumping this one for Andy B

You may remember him from his previous hits such as...

"William Fischer, M.D., University of North Carolina (UNC), a lead investigator of SNG001 said: "These results, including a decrease in hospitalisations and adverse events among participants who received SNG001, are promising and warrant further investigation in a larger Phase 3 clinical trial. SNG001 is the first nebulized inhaled therapeutic to demonstrate promising results and, if confirmed in larger studies, could represent a potential treatment option for people who have COVID-19 but are not hospitalised."

Read it again Doc ;-)

https://twitter.com/Synairgenplc/status/1628003313764470786?t=KbPEuiCZbl4o19_MWYM_yA&s=19

For #media #attendees #investors

Meet us today in #Seattle at #CROI2023 & join #SNG CSO @PhillMonk for @WFischerII presentation on Safety and Efficacy of Inhaled Interferon-B1a in Outpatients with COVID-19 data from ACTIV-2 Phase 2 trial at 10:29 am Pacific Time #antivirals

West coast so will be after market close. Haven't seen an option to watch live online as of yet. Pls share if anyone does.

Nice timing RB. He's since RT'd again and replied to a comment on SnG.

That big trade shows as a buy on vox markets

Great point regarding prophylactic use of interferon Andy, thumbs up champ.

(Wonder what it is about this thread that's got him pulling out all the old one liners trying to start a fight and get it removed?) Hmmmm.

The prophylactic effect of inf is well documented. With published studies as far back as the 60s documenting efficacy at preventing disease. However the major stumbling block had always been the associated side effects of systematic or simple nasal spray applications. Given the now proven safety record of inhaled INFb, it would be right and correct to study it's potential as a prophylactic and/or a post exposure treatment.

Ftc7 - top tip for you: Google "interferon + prophylactic"

The science is well established